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ABSTRACT
Introduction. The impact of dyspepsia guidelines on clinical prac-
tice may be poor. Provider adherence with dyspepsia guidelines was 
examined to determine their impact on clinical practice. 
Methods.xProvider adherence with the 2005 American College of 
Gastroenterology Guidelines for the Management of Dyspepsia and 
the 2017 American College of Gastroenterology and Canadian Asso-
ciation of Gastroenterology joint Dyspepsia Management Guidelines 
was assessed on a national level using data from the National Ambu-
latory Medical Care Survey (NAMCS). Patient visit data, including 
reason for visit of dyspepsia, diagnosis of dyspepsia, or diagnosis 
of H. pylori infection from NAMCS years 2012 through 2015, were 
used. Provider adherence with dyspepsia management guidelines was 
determined based upon provision of at least one recommended test or 
treatment for dyspepsia. 
Results. Providers appeared to adhere to the 2005 ACG guidelines 
for 49.7% of patient visits. Providers appeared to adhere to the 2017 
ACG/CAG guidelines for 51.0% of patient visits.
Conclusion. Provider adherence with the 2005 ACG and the 2017 
ACG/CAG Dyspepsia Management Guidelines was determined to 
be low in this study, highlighting the need to increase evidence-based 
medical treatment and efficient resource use for dyspepsia. 
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INTRODUCTION
Dyspepsia has been described as epigastric pain persisting for one 
month or more, which may be associated with a range of other clinical 
gastrointestinal symptoms, including heartburn or epigastric full-
ness.1 The prevalence of uninvestigated dyspepsia in North America 
is approximately 22%, with a suggested incidence of 1.3% annually 
and peak incidence in the seventh decade of life.2,3 
Dyspepsia patients can be categorized as (1) uninvestigated if they 
have not undergone investigation in an attempt to discover underlying 
disease, (2) investigated, which exposed a cause for their symptoms, or 
(3) investigated, but no cause was discovered, termed functional dys-
pepsia, a diagnosis of exclusion.4 Investigation by endoscopy revealed 
clinically significant findings in 10.2% of patients, with one study sug-
gesting nonerosive gastritis and another suggesting reflux esophagitis 
most commonly, were identified.5,6 Other underlying causes of dys-
pepsia included infection of Helicobacter pylori (H. pylori), gastric or 
duodenal ulcers, and gastrointestinal malignancy, although functional 
dyspepsia is the most common cause.4,7 
Different tests and procedures may be done to investigate dyspep-
sia symptoms, some of which are not recommended routinely and may 
increase healthcare costs for dyspepsia management. Among patients 
diagnosed with functional dyspepsia, the cost of testing received was 
estimated to be $582 per patient.8 These patients underwent blood 
work (75%), abdominal ultrasound (59%), abdominal x-ray (47%), or 
abdominal and/or pelvis computed tomography (CT; 40%).8 None of 
these tests are recommended routinely for evaluation of dyspepsia by 
either the 2005 American College of Gastroenterology clinical guide-
lines or the 2017 American College of Gastroenterology and Canadian 
Association of Gastroenterology joint guidelines.1,9
The impact of dyspepsia guidelines on clinical practice may be 
poor. A vignette survey suggested 57% of primary care providers and 
74% of gastroenterologists adhered to the 2005 ACG guidelines and 
other consensus recommendations for dyspepsia investigation and 
management.10
Endoscopy may be overutilized to investigate dyspepsia. One study 
suggested 37.8% of esophagogastroduodenoscopies (EGD) done for 
gastrointestinal indications, including dyspepsia, were not indicated 
by guidelines.11 A study of dyspepsia patients younger than 55 years 
without alarm symptoms suggested 58% (rather than 100%) had 
received both H. pylori testing and proton pump inhibitors (PPI) 
therapy, as the guidelines recommended, before receiving an EGD.12 
However, endoscopy may be underutilized in older age groups, as one 
study reported 81% of dyspepsia patients 50 years or older had not 
received endoscopy, despite guideline recommendations.13 Another 
study reported similar results; only 27% of dyspepsia patients older 
than 55 years had received an EGD, rather than 100% if the 2005 
guidelines had been followed.3 
The current study examined dyspepsia investigation and treat-
ment practices for 2012 - 2015. Provider practices were determined 
to be adherent or nonadherent with the 2005 ACG Guidelines for 
the Management of Dyspepsia. Adherence with the 2017 ACG and 
CAG guidelines also was assessed to determine if clinical practices in 
the years preceding the release of these guidelines had shifted toward 
utilizing therapies included in  the 2017 guidelines, as new knowledge 
on effective management was identified, but before updated guide-
lines were released.
METHODS
Participants. Data were analyzed from the National Ambu-
latory Medical Care Survey (NAMCS) for 2012 - 2015.14 Data 
collected about community health centers were not included. Patient 
data meeting the following criteria were included: reason(s) for visit 
including dyspepsia, diagnosis of dyspepsia, or diagnosis of Helico-
bacter pylori infection. Data were excluded if patients were younger 
than 18 years, or if the patient had a diagnosis of gastroesophageal 
reflux disease (GERD).
Instrument. Non-federally employed, practicing physicians 
(excluding pathologists, radiologists, and anesthesiologists) working 
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in NAMCS. Physician interviews were used to collect physician 
and healthcare practice data (e.g., specialty, location). Physicians 
were surveyed for a sample of patient visits during a random one-
week period annually. Data recorded about patient visits included 
demographic information, patient comorbidities, reason(s) for visit, 
diagnoses related to the visit, services ordered or provided, medica-
tions (including prescription and over-the-counter drugs) ordered 
or provided, and if these medications were new or continued. Drug 
information, including drug therapeutic classes, for medications 
ordered or provided during the patient visit, was coded by NAMCS 
using Lexicon Plus®, a Cerner Multum™, Inc. database.15
The variables used from the NAMCS database files for the current 
study included patient age, body mass index (BMI), sex, unimput-
ed race, unimputed ethnicity, tobacco use, depression comorbidity, 
reason for visit, diagnoses related to visit, services ordered or provid-
ed, and therapeutic class codes for medications ordered or provided. 
Up to five reasons for visit and five diagnoses could be listed per 
patient record. For services not specifically listed as a checkbox item 
on the patient record interview form, up to nine write-in procedure 
codes could be documented. Up to 10 medications could be listed for 
years 2012 and 2013, and up to 30 medications could be listed for 
years 2014 and 2015. For each medication, up to four categories, with 
three levels per category, could be used to list the drug’s therapeutic 
class codes from the Lexicon Plus® database.15 
Data about the physician, including specialty and region of prac-
tice within the U.S., were used. Physician specialty was stratified into 
14 groups, including general/family practice, internal medicine, and 
general surgery. Physician specialty was stratified separately into 
three groups: primary care, surgical care, or medical care specialties. 
Regions of practice included the northeast, midwest, south, and west 
regions of the U.S. 
Procedures. This study was considered “not human subjects” by 
the University of Kansas School of Medicine-Wichita’s Human Sub-
jects Committee. To assess the frequency of medications ordered or 
prescribed, drug therapeutic class codes were used. Drug therapeutic 
classes of interest included antacids, PPIs, H2 antagonists, H. pylori 
eradication agents, gastrointestinal stimulants, and tricyclic antide-
pressants (TCA). 
The frequency of a diagnosis of H. pylori infection (ICD-9-CM 
code 041.86) along with one or more write-in procedure codes 
encompassing noninvasive H. pylori testing recommended by the 
2007 ACG H. pylori management guidelines was used to determine 
the frequency H. pylori tests were ordered or provided16 (Table 1).
Table 1. Patient characteristics.
89.39 Other nonoperative measurements and examinations (includ-
ing 14 C-Urea breath test).
90.59 Other microscopic examination of blood.
90.99 Other microscopic examination of specimen from lower gas-
trointestinal tract and of stool.
91.39 Other microscopic examination of specimen from bladder, 
urethra, prostate, seminal vesicle, perivesical tissue, and of 
urine and semen.
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To assess the frequency of EGD or other upper gastrointestinal 
endoscopy ordered or provided during a patient visit, data from the 
checkbox item “upper gastrointestinal endoscopy/EGD” for years 
2014 and 2015 were combined with write-in upper endoscopy 
ICD-9-CM procedure codes for years 2012 through 2015 (Table 2). 
The combined frequency of the EGD checkbox item and the upper 
endoscopy procedure codes was used to assess the number of upper 
endoscopies ordered or performed.
Table 2. Write-in upper endoscopy ICD-9-CM procedure codes.
42.23 Other esophagoscopy (excludes that with biopsy).
42.24 Closed [endoscopic] biopsy of esophagus.
44.13 Other gastroscopy (excludes that with biopsy).
44.14 Closed [endoscopic] biopsy of stomach.
45.13 Other endoscopy of small intestine (includes EGD).
45.16 EGD with closed biopsy.
To assess provider adherence with the 2005 ACG guidelines, the 
provision of at least one component of the 2005 guidelines constituted 
adherence. Specifically, the provision of any upper endoscopy/EGD, 
acid suppression medication (PPIs), H. pylori eradication agents, or 
noninvasive H. pylori testing was assessed per patient to determine 
provider guideline adherence (Figure 1). To assess provider adher-
ence with the 2017 ACG/CAG guidelines, the provision of at least 
one component of the 2017 guidelines constituted adherence. All 
components of the 2005 guidelines were included in the 2017 assess-
ment, with the addition of tricyclic antidepressant medications, GI 
stimulant/prokinetic medications, or psychotherapy (Figure 1). H2 
antagonists were included as acceptable acid suppression therapy 
for adherence with the 2005 and 2017 guidelines in two additional 
assessments of provider adherence.
Figure 1. Criteria for guideline adherence.
Analysis. Data were analyzed using SAS version 9.4 (2019, SAS Int. 
Inc., Carry, NC). Frequencies, proportion, means, and standard devia-
tions were calculated. Pearson chi-square and likelihood chi-square 
were used to test the associations between categorical variables. 
Cochran-Mantel-Haenszel statistics were conducted to deter-
mine the relationships between two stratified categorical variables 
after controlling for at least one variable. These stratified analyses 
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provided a way to adjust for the possible confounding effects without 
being forced to estimate parameters for them. All statistical tests at p 
≤ 0.05 were considered significant.
RESULTS
Of the 260,118 patient encounters from 2012 through 2015, 680 
records met inclusion/exclusion criteria. Of the 680 records, heart-
burn and indigestion (dyspepsia; ICD-9-CM code 1535.0) was 
documented as the reason for 58.5% of patient visits (n = 398). The 
diagnosis of dyspepsia or other specified disorders (ICD-9-CM code 
536.8) was listed for 38.2% of patients (n = 260), and the diagnosis 
of H. pylori infection (ICD-9-CM code 041.86) was listed for 13.1% 
of patients (n = 89). 
Physician participants worked throughout the U.S., with 34.4% 
practicing primarily in southern states (n = 234), 23.1% in western 
states (n = 157), 23.1% in the midwest (n = 157), and 19.4% in the 
northeast (n = 132). Broadly grouped, 49.0% of physicians (n = 333) 
were in medical care specialties, 42.2% of physicians (n = 287) were 
in primary care specialties, and 8.8% of physicians (n = 60) were in 
surgical care specialties. Of the 14 specialty groupings, many physi-
cians (41.0%, n = 194) were categorized into the “other” specialties 
group, which included gastroenterology. Physicians in the “general or 
family practice” group made up 20.9% of participants (n = 99), and 
those in internal medicine made up another 20.9% of participants 
(n = 99). 
As reported by their physicians, most patients (82.3%, n = 415) 
were White, and 9.9% of patients (n = 50) were Black or African 
American. Almost 20% of patients (18.2%, n = 88) were reported to 
be Hispanic or Latino (Table 3).
Table 3. Patient demographics.
Frequency Percent
Sex
Female 411 60.4%
Male 269 39.6%
Ethnicity
Not Hispanic/Latino 396 81.8%
Hispanic/Latino 88 18.2%
Missing 196
Race
White/Caucasian 415 82.3%
Black/African American 50 9.9%
Asian American 33 6.5%
More than 1 Race Reported 3 0.6%
Native Hawaiian/Other Pacific Islander 2 0.4%
American Indian/Alaskan Native 1 0.2%
Missing 176
Patient mean age was 55 years, and 60.4% of patients (n = 411) 
were female. Mean patient BMI (n = 521) was 29. Physicians reported 
that 16.5% of patients (n = 90) were current tobacco users and 10.6% 
of patients (n = 72) had current depression. 
Almost all patients (91.8%, n = 624) had at least one service ordered 
or provided, including exams, screenings, laboratory tests, imaging, 
procedures, treatments, health education, or counseling. More than 
one quarter of physicians (26.3%, n = 179) reported having one or 
more exams ordered or provided. Almost one in five patients (18.5%, 
n = 126) had some type of imaging ordered or provided, including an 
x-ray for 7.2% of patients (n = 49), CT scan for 4.9% of patients (n = 
33), or magnetic resonance imaging for 1.3% of patients (n = 9). 
One or more write-in procedures were reported for 43.4% of 
patients (n = 295), for a total of 486 write-in procedures. Procedures 
included “other microscopic examination of blood” (17.5%, n = 85), 
upper endoscopy (13.8%, n = 67), “other consultation” (10.1%, n = 
49), and general physical examination (3.5%, n = 17).
Of prescription and non-prescription medications reported, ant-
acids were ordered or provided for 3.8% of patients (n = 26). Of the 
acid suppression medications, PPIs (41.3%, n = 281) were ordered or 
provided more often than H2 antagonists (7.9%, n = 54). TCAs were 
ordered or provided for 1.8% of patients (n = 12), and GI stimulants/
prokinetics were ordered or provided for 1.6% of patients (n = 11). 
Psychotherapy was ordered or provided for 0.6% of patients (n = 4). 
Noninvasive H. pylori testing was ordered or provided for 2.9% of 
patients (n = 20). H. pylori eradication therapy was given for 1.6% of 
patients (n = 11). Any EGD/upper endoscopy was ordered or pro-
vided for 12.8% of patients (n = 87; Table 4).
Table 4. Management provided.
Frequency Percent 
Medications (Prescription and Non-Prescription)
Proton Pump Inhibitors (PPIs) 281 41.3%
H2 Antagonists 54 7.9%
Antacids 26 3.8%
Tricyclic Antidepressants (TCA) 12 1.8%
GI Stimulants/Prokinetics 11 1.6%
H. pylori Testing or Treatment
Noninvasive H. pylori Test 20 2.9%
H. pylori Eradication Therapy 11 1.6%
EGD/Upper Endoscopy
EGD/Upper Endoscopy 87 12.8%
When adherence was defined as provision of any component of the 
2005 ACG dyspepsia guidelines, providers were considered adherent 
for 49.7% (n = 338) of patient visits. When adherence was defined 
as provision of any component of the 2017 ACG/CAG dyspepsia 
guidelines, providers were considered adherent for 51.0% (n = 347) 
of patient visits (Table 5). Addition of H2 antagonists for acceptable 
acid suppression raised adherence to 54.1% of patient visits (n = 368) 
for the 2005 ACG guidelines and 55.4% of patient visits (n = 377) for 
the 2017 ACG/CAG guidelines.
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Frequency Percent
2005 ACG Guideline Criteria
Total Adherence from 2012 through 2015 338 49.7%
Adherence in 2012 95 45.9%
Adherence in 2013 152 53.1%
Adherence in 2014 67 52.8%
Adherence in 2015 24 40.0%
2017 ACG/CAG Guideline Criteria
Total Adherence from 2012 through 2015 347 51.0%
Adherence in 2012 95 45.9%
Adherence in 2013 154 53.8%
Adherence in 2014 72 56.7%
Adherence in 2015 26 43.3%
DISCUSSION
The prevalence of dyspepsia in this study was 0.26% (n = 680). A 
prior study suggested the prevalence of gastritis/dyspepsia to be 1.73% 
among adults.17 The lower prevalence of dyspepsia within this study 
may be due to the strict inclusion criteria. It is likely that some patients 
presenting with dyspepsia were not reported as such by physicians 
during the patient record interview, and instead another reason for 
visit or diagnosis was used, such as upper abdominal pain (ICD-9-CM 
code 1545.3 upper abdominal pain, cramps, spasms) or diagnosis of 
gastric ulcer (ICD-9-CM code 531 Gastric Ulcer). The code for upper 
abdominal pain was not used for inclusion criteria in this study, as it 
encompasses more than just epigastric pain and likely would have over-
estimated the prevalence of dyspeptic patients within the study sample. 
Likewise, more specific diagnoses, such as gastric ulcers or gastrointes-
tinal malignancy, were not used for inclusion criteria in this study, as 
they are considered underlying causes of dyspepsia identified on EGD 
which may require separate therapy.18,19 
Diagnosis of H. pylori infection was used for inclusion criteria in 
this study, as the 2007 ACG Guideline on the Management of Helico-
bacter pylori Infection recommended diagnosis and treatment for select 
patients with uninvestigated dyspepsia.16 Although diagnosis of H. pylori 
is indicated for reasons other than dyspepsia (e.g., peptic ulcer disease, 
gastric mucosa associated lymphoid tissue or MALT lymphoma), the 
diagnosis of H. pylori was used to identify a small proportion (13.1%) of 
the study sample and is unlikely to have a large impact on the results.16 
The diagnosis of GERD was used for exclusion, as GERD is considered 
a different diagnosis for patients presenting mainly with heartburn or 
acid regurgitation, rather than dominant epigastric discomfort or pain 
as in dyspepsia.9 
The current study suggested dyspepsia to be more common among 
women. Uninvestigated dyspepsia may be more common among 
women, with a suggested global prevalence of 25.3% in women com-
pared to 21.9% among men.2 Patient mean age in this study was 55 years, 
which is slightly older than the mean ages of 47 years and 50 years of 
two other studies of patients with dyspepsia.8,20 
In the current study, 18.5% of patients (n = 126) were ordered or pro-
vided an imaging service. A study of patients with persistent dyspepsia 
suggested that 87.1% of patients had received abdominal imaging, and
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 the most frequent modalities were CT and ultrasound.21 The lower fre-
quency of imaging use in the current study could indicate a decreasing 
trend as study data were obtained from more recent years, although 
history of prior or later imaging services provided to patients in this 
study was not obtainable. 
The current study suggested that PPIs were prescribed more often 
than H2 antagonists. Physician concern about adverse effects of PPI 
therapy have been suggested, with 52% of internal medicine physicians 
self-reporting they sometimes or often changed a patient’s prescrip-
tion from PPI therapy to H2 antagonists.22 A prior study suggested 
H2 antagonists were prescribed more frequently than PPIs in patients 
with uninvestigated dyspepsia (88.1% versus 47.4%, respectively).13 
However, the current study’s findings were consistent with guideline 
recommendations, and this increased usage of PPIs over H2 antago-
nists for acid suppression therapy may indicate guideline adherence in 
this area.1,9
Half of patients with dyspepsia in this study received at least one treat-
ment, diagnostic test, or exam recommended by either the 2005 ACG 
or 2017 ACG/CAG guidelines. This percentage of patients receiving 
care specified within dyspepsia management guidelines was subopti-
mal and indicated low physician adherence to dyspepsia management 
guidelines. Furthermore, there was minimal difference between the 
percent of visits adherent to the 2005 compared to the 2017 guidelines, 
indicating the additional therapies considered adherent by the 2017 
guidelines were not utilized frequently in the years preceding the release 
of the 2017 guidelines. This limited difference in adherence also clari-
fied that most visits considered non-adherent with the 2005 guidelines 
were not provided the more novel therapies considered to be adherent 
by the 2017 guidelines. 
Physicians may be non-adherent due to lack of knowledge of guide-
lines. A review of guideline adherence barriers suggested physicians 
were more likely to be unfamiliar with guideline content than unaware 
of their existence.23 Therefore, dissemination of the 2017 ACG/CAG 
guidelines with its management algorithm to physicians working in 
ambulatory care settings may improve knowledge and adherence to 
dyspepsia management guidelines. However, this strategy alone may 
not be sufficient to raise adherence levels, as passive dissemination of 
guidelines has been suggested to be ineffective for guideline implemen-
tation.24 Further interventions, including workshops, handouts, and 
reminders, may be beneficial as they have been suggested to lower drug 
costs of dyspepsia without increasing endoscopy use.25 
Increased monitoring of guideline adherence in clinical practices 
may be beneficial. Notifying providers when their endoscopy referral 
for dyspepsia management was not adherent with guidelines was sug-
gested to increase adherence rates from 55% to 75%.26 Less targeted 
approaches to increase physician acceptance and adherence to all clini-
cal guidelines may be useful, as one study suggested clinical practice 
guidelines only have a large or very large effect on how less than 25% of 
physicians practice medicine.27 Both targeted and general approaches 
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to increase guideline adherence may be necessary to ensure evidence-
based medicine is practiced. 
There were several limitations of this study. NAMCS is a voluntary 
survey of physicians. As a result, data may be influenced by response 
and/or recall bias. There was also variability in the number of records 
meeting inclusion/exclusion criteria per year. The highest number of 
patient records meeting criteria for this study was 286 records in 2013 
and the lowest number was 60 in 2015. The lack of consistency in the 
total number of patient records available per year from the NAMCS 
database may have led to increased variability in the data. However, 
the percentage of records determined to be adherent to guidelines in 
this study remained low in each year, ranging from 40.0% to 53.1% for 
the 2005 guidelines and from 43.3% to 56.7% for the 2017 guidelines.
The lack of available CPT codes, the broadness of the ICD-9-
CM codes, and the variability in the checkbox items included in the 
survey from year to year made capturing accurate and consistent data 
difficult. For example, upper gastrointestinal endoscopy/EGD was 
included as a checkbox item for examinations/screenings ordered or 
provided for survey years 2014 and 2015, but not for years 2012 or 
2013. Furthermore, appropriateness of the use of treatments or tests 
for each patient based upon specific indications (such as presence 
of alarm features, risk of malignancy, or previous treatment or test 
results) could not be assessed in this cross-sectional study. Addition-
ally, some patients may have not desired or had counter-indications 
to receiving the guideline recommended test or treatment, making 
non-adherence acceptable in these specific situations. Therefore, 
adherence may have been over or underestimated, as the specific 
order and situational appropriateness of guideline provision could 
not be assessed. 
Despite the challenges of using NAMCS data, the survey captured 
national, systematic data on ambulatory care practices within the U.S. 
It is a valuable source of information about clinical practices of U.S. 
physicians.
CONCLUSIONS
Provider adherence with both the 2005 ACG and the 2017 ACG/
CAG dyspepsia management guidelines was determined to be low 
in this study, with 50% of patients receiving a recommended test or 
treatment. Physician adherence must increase to evidence-based 
management of patients with dyspepsia and utilize healthcare 
resources appropriately and efficiently.
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